JournalsHub
.online
Find My Journal
MG

M R Green

International Drug Development FR

6
Publications
6,251
Citations
5
H-Index
5
i10-Index
0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg +9 more
Journal of Clinical Oncology 1997
5,871
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg +9 more
Journal of Clinical Oncology 2023
169
Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer.
Rogério Lilenbaum, M R Green
Journal of Clinical Oncology 1993
129
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Raymond P. Abratt, Alan Sandler, Lucio Crinò, W P Steward, Frances A. Shepherd +3 more
PubMed 1998
62
Multimodality therapy for non-small-cell lung cancer
Rogério Lilenbaum, M R Green
Lung Cancer 1995
16

Publications

6 total

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg et al. - Journal of Clinical Oncology, 2023
Cited by 169 OpenAlex

Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.

Federico Cappuzzo, Caio M. Rocha Lima, Cynthia A. Sherman, M R Green - PubMed, 2000
Cited by 4 OpenAlex

Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.

Raymond P. Abratt, Alan Sandler, Lucio Crinò, W P Steward, Frances A. Shepherd et al. - PubMed, 1998
Cited by 62 OpenAlex

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg et al. - Journal of Clinical Oncology, 1997
Cited by 5,871 OpenAlex

Multimodality therapy for non-small-cell lung cancer

Rogério Lilenbaum, M R Green - Lung Cancer, 1995
Cited by 16 OpenAlex

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer.

Rogério Lilenbaum, M R Green - Journal of Clinical Oncology, 1993
Cited by 129 OpenAlex

Research Topics

Lung Cancer Treatments and Mutations (4) Cancer Treatment and Pharmacology (3) Pancreatic and Hepatic Oncology Research (2) Hepatocellular Carcinoma Treatment and Prognosis (1) Lung Cancer Diagnosis and Treatment (1)

Frequent Co-Authors

HO
Howard A. Burris
2 joint publications
MA
Malcolm J. Moore
2 joint publications
JO
John Sahl Andersen
2 joint publications
MA
Mace L. Rothenberg
2 joint publications
MA
Manuel Modiano
2 joint publications
M.
M. Christine Cripps
2 joint publications

Affiliations

The University of Texas Health Science Center at San Antonio
US 1997 - 1997
International Drug Development
FR 2023 - 2023

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now